L
Lyell Immunopharma
South San Francisco, United States
Founded 2018 NASDAQ: LYEL
Cell Therapy Nano Cancer Nanotherapy Nanomedicine Protein Nanoparticles Nano-Bio Gene Therapy Delivery
About
T cell reprogramming company developing next-generation cell therapies for solid tumors
Company Details
- Type
- public
- Employees
- 300+
- Funding
- Public
Key Products
- LYL845
- LYL797
- Gen-R Technology